疾病进展或死亡风险降低85%!精准疗法3期临床结果积极(2)
2019-10-12 未知 admin
“今天宣布的消息是我们开发创新癌症治疗的重要里程碑,”Deciphera公司总裁兼首席执行官Steve Hoerter先生表示:“在此,我代表整个Deciphera团队,感谢参与临床试验INVICTUS的患者和医护人员。INVICTUS的研究数据使我们坚信,ripretinib有很大可能改变GIST的治疗现状,现在我们的工作重点是与美国FDA进行密切合作,为那些先前已接受治疗但失败的GIST患者提供急需的治疗方案。”
参考资料:
[1] Deciphera Pharmaceuticals Announces Positive Top-line Results from INVICTUS Pivotal Phase 3 Clinical Study of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors. Retrieved August 13, 2019, from https://www.businesswire.com/news/home/20190813005228/en/Deciphera-Pharmaceuticals-Announces-Positive-Top-line-Results-INVICTUS
[2] Deciphera Pharmaceuticals. Retrieved August 13, 2019,fromhttps://www.deciphera.com/
原标题:速递 | 降低癌症进展和死亡风险85%!精准疗法3期试验结果积极
▽关注【药明康德】微信公众号
鐑瘝锛